Heart Failure
Conditions
Brief summary
The goal of this observational study is to learn about the influencing factors of chronic heart failure prognosis in heart failure patients. The main question it aims to answer is that what are the influencing factors of clinical outcomes in chronic heart failure. Participants will be collected multiple omics data such as phenotype group, environmental exposure group, intestinal microbiome, genome, metabolome, and noninvasive biomarkers.
Interventions
BEHAVIORALRemote monitoring assisted by community physicians
Patients upload data such as wristband data, blood pressure, weight through their mobile phones, while physicians can check the data on the platform. Upon detecting alerts, community physicians review participant-related medical information, conduct structured symptom assessments via "StarNet Home" platform/phone within 2 hours, and initiate protocol-guided interventions (e.g., diuretic adjustment for fluid overload).
Sponsors
Jiangsu Taizhou People's Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥18 years; 2. Fulfill at least one of the following criteria：①History of chronic heart failure;②New-onset heart failure with LVEF \<50%；③New-onset heart failure with LVEF≧50%，E/e'≧15 and BNP\>400 pg/mL/NT-proBNP(\<50 years, \>450 pg/mL; 50\~75 years, \>900 pg/mL; \>75 years, \>1800 pg/mL) 3. Etiology: dilated cardiomyopathy, hypertensive heart disease, ischaemic cardiomyopathy, Non-severe valvular heart disease； 4. Primary post-discharge therapy: oral medication; 5. Sign the informed consent form.
Exclusion criteria
1. Patients with renal failure (Ccr\<30ml/min) or patients on dialysis therapy; 2. Various correctable secondary causes of cardiac insufficiency including hyperthyroid heart disease, anaemic heart disease, uncorrected congenital heart disease; severe valvular heart disease (including severe stenosis or closure of organic aortic and mitral valves); 3. Patients with indications for pacemaker implantation but have not received a pacemaker implant; 4. Patients with chronic obstructive pulmonary disease accompanied by type II respiratory failure. 5. Patients who cannot understand and sign an informed consent form. 6. Patients with mental illness, pregnant women, and other special populations.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| incidence of composite event (cardiovascular mortality, unplanned HF hospitalization, emergency HF intervention) | 2 years | Cardiovascular disease death, heart failure readmission and emergency HF intervention are three endpoint events, with either occurring as the primary endpoint |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| all-cause mortality | 2 years | all-cause mortality |
Countries
China
Contacts
CONTACTYucheng Wu, Doctor
CONTACTLichun Wang, Master
PRINCIPAL_INVESTIGATORMing Chu, Doctor
Jiangsu Taizhou People's Hospital
Outcome results
None listed